A $100M+ run-rate from the Texas plant, with utilization at 63% and a $200M FY28 target in sight—growth is compounding, though the market has already priced in the full landing.
Overall read
7.1/10
Priced for it
The three reads · this quarter
A $100M+ run-rate from the Texas plant, with utilization at 63% and a $200M FY28 target in sight—growth is compounding, though the market has already priced in the full landing.
Overall read
7.1/10
Priced for it
The three reads · this quarter
The standing reads · change less often
Moat
Moderate edge
Moat anchored in customer relationships and cross-industry formulation know-how, but limited by cyclical end-markets and modest scale.
Key variables
4 tracked
lead: Capacity utilizationUtilization at the Texas plant remains below ~63%, leaving significant headroom to ramp production and drive organic revenue growth without major capex.
Walk the talk
Not enough data
as of Q1 FY27CrudeChem capacity doubled to 148K MTPA; utilization at 63% with headroom to 100%.
Latest · newest first
5d ago · Credit Rating
ICRA upgraded LT rating to AA- from A+; outlook revised to Stable from Positive
5d ago · Credit Rating
ICRA upgraded LT rating to AA- from A+; outlook revised to Stable from Positive
24 Jul 2026 · Business Update
Company announces Q1 FY26-27 earnings update via press release.
0 of 0 guidance items delivered on time
Where it sits